Bromocriptinedrug info
bromocriptine 5 MG Oral Capsule
What it is used for
1 INDICATIONS & USAGE Bromocriptine mesylate is an ergot derivative indicated for the treatment of: Hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility, or hypogonadism in adults Prolactin-secreting adenomas in adults and pediatric patients 11 years of age and older. Acromegaly in adults. Signs and symptoms of idiopathic Parkinson’s disease or postencephalitic parkinsonism in adults. Limitations of Use Avoid use of bromocriptine mesylate for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions
1.1 Hyperprolactinemia-Associated
Dysfunction Bromocriptine mesylate is indicated for the treatment of hyperprolactinemia-associated dysfunction including amenorrhea with or without galactorrhea, infertility or hypogonadism in adults. Limitations of Use Avoid use of bromocriptine mesylate for the inhibition or suppression of postpartum physiologic lactation because of the risk of serious adverse reactions.
1.2 Prolactin-Secreting
Adenomas Bromocriptine mesylate is indicated for the treatment of prolactin-secreting adenomas in adults and pediatric patients 11 years of age and older.
1.3 Acromegaly
Bromocriptine mesylate is indicated for the treatment of acromegaly in adults.
1.4 Idiopathic
Parkinson’s Disease or Postencephalitic Parkinsonism Bromocriptine mesylate is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease or postencephalitic parkinsonism in adults.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective July 27, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
Description
Bromocriptine mesylate is an ergot derivative with potent dopamine receptor agonist activity. Bromocriptine mesylate is chemically designated as Ergotaman-3′, 6′, 18-trione, 2-bromo-12′hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)-, (5′α)-monomethanesulfonate (salt).
The structural formula is: Complies with USP dissolution test 1. Bromocriptine mesylate tablets and Bromocriptine mesylate capsules are for oral administration.
Bromocriptine mesylate tablets: Each tablet contains 2.5 mg of bromocriptine (equivalent to 2.87 mg of bromocriptine mesylate) and the following inactive ingredients: colloidal silicon dioxide, lactose monohydrate, magnesium stearate, maleic acid, povidone and corn starch.
Bromocriptine mesylate capsules: Each capsule contains 5 mg of bromocriptine (equivalent to 5.74 mg of bromocriptine mesylate) and the following inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, and maleic acid. The hard gelatin capsule contains gelatin, iron oxide red, titanium dioxide and purified water. The imprinting ink contains black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, propylene glycol and shellac. structure
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective July 27, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance